Supplementary Table 1. Weight definitions for EQ-5D-5L dimensions and levels
EQ-5D-5L Dimension Weight
Mobility
Slight 0.058
Moderate 0.076
Severe 0.207
Unable 0.274
Self-care
Slight 0.050
Moderate 0.080
Severe 0.164
Unable 0.203
Usual activities
Slight 0.050
Moderate 0.063
Severe 0.162
Unable 0.184
Pain/discomfort
Slight 0.063
Moderate 0.084
Severe 0.276
Extreme 0.335
Anxiety/depression
Slight 0.078
Moderate 0.104
Severe 0.285
Extreme 0.289
‘No problem’ was weighted as 0
If the weight of any dimension was missing the utility index was not computed EQ-5D-5L, EuroQol five dimensions five levels
Supplementary Table 2. VFQ-25 questionnaire scoring Scoring key: recoding of items
Item numbers Original response
categorya Recoded value
1,3,4,15cb 1 100
2 75
3 50
4 25
5 0
2 1 100
2 80
3 60
4 40
5 20
6 0
5–14, 16, 16a, A3–A9c 1 100
2 75
3 50
4 25
5 0
6 d
17–25, A11a, A11b, A12, A13
1 0
2 25
3 50
4 75
5 100
A1, A2 0 to 10 0 to 100
VFQ sub-scales
Scale Number of items Items to be averaged (after recoding)
General health 2 1
General vision 2 2
Ocular pain 2 4, 19
Near activities 6 5, 6, 7, A3–A5
Distance activities 6 8, 9, 14, A6–A8
Vision specific
Social functioning 3 11, 13
Mental health 5 3, 21, 22, 25
Role difficulties 4 17, 18
Dependency 4 20, 23, 24
Driving 3 15c, 16, 16a
Color vision 1 12
Peripheral vision 1 10
aPrecoded response choices as printed in the questionnaire
bItem 15c has four response levels, but was expanded to five levels using item 15b. Note: If 15b=1, item 15c was recoded to ‘0’ and if 15b=2 or 3, item 15c was recoded to missing
c‘A’ indicates an optional item from the Appendix. If optional items are used, NEI-VFQ developers encourage users to use all items for a given sub-scale to enhance the comparability of sub-scale scores across studies
dResponse choice ‘6’ indicates a patient who does not perform the activity due to non–vision-related problems. If this choice is selected, the item is coded as “missing”
NEI, National Eye Institute; VFQ-25, Visual Function Questionnaire
Supplementary Table 3. WPAI-UV (Uveitis 2.0) questionnaire Question
Q1 Are you currently employed (working for pay, yes/no)?
Q2 During the past seven days, how many hours did you miss from work because of problems associated with your uveitis?
Q3 During the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?
Q4 During the past seven days, how many hours did you actually work?
Q5 During the past seven days, how much time did your uveitis affect your productivity while you were working? (0=uveitis had no effect on my work;
10=uveitis completely prevented me from working)
Q6 During the past seven days, how much did your uveitis affect your ability to do your regular daily activities, other than work at a job? (0=uveitis had no effect on my daily activities; 10=uveitis completely prevented me from doing my daily activities)
WPAI-UV, Work Productivity and Activity Impairment - Uveitis
Supplementary Table 4. Conversion table for visual acuity [1]
Ranges (ICD-9-CM) Decimal logMAR
(Near-) Normal vision
Normal vision 1.6
1.25 1.0 0.8
-0.2 -0.1 0 +0.1
Mild vision loss 0.63
0.5 0.4 0.32
0.2 0.3 0.4 0.5 Low vision
Moderate vision loss 0.25
0.20 0.16 0.125
0.6 0.7 0.8 0.9
Severe vision loss 0.10
0.08 0.063
0.05
+1.0 1.1 1.2 1.3
Profound vision loss 0.04
0.03 0.025
0.02
1.4 1.5 1.6 1.7 (Near-) blindness
Near-blindness 0.016
0.0125 0.01
1.8 1.9 +2.0
Blindness No light perception
ICD-9-CM, International Classification of Diseases, 9th revision, Clinical Modification; logMAR, logarithm of the minimum angle of resolution
Supplementary Table 5. List of participating sites
Institution (Hospital) City Country
Private practices Buenos Aires Argentina
Organización Médica de Investigación Buenos Aires Argentina Universidade Federal de São Paulo -
Departamento de Oftalmologia
São Paulo-SP Brazil
Hospital Oftalmológico de Sorocaba Sorocaba - SP Brazil Hospital São Geraldo (UFMG) Santa Efigênia - Belo
Horizonte
Brazil Hospital Universitário Cassiano Antônio de
Moraes (UFES)
Santa Cecilia, Vitória - ES
Brazil Berner Augenklinik am Lindenhofspital Bern Switzerland
Stadtspital Triemli Augenklinik Zürich Switzerland
Hospital del Salvador Santiago Chile
Clinica Oftalmologica del caribe Barranquilla Colombia Fundación Oftalmologica de Santander -
FOSCAL
Bucaramanga Colombia
Fundacion Valle del Lili Cali Colombia
Všeobecná fakultní nemocnice v Praze Prague Czech
Republic
Clinical Hospital Center Zagreb Zagreb Croatia
Clinical Hospital Center Osijek Osijek Croatia
Clinical Hospital Center Rijeka Rijeka Croatia
Galilee Medical Center Nahariya Israel
Rabin Medical Center Petah Tikva Israel
Hadassah Medical Center Jerusalem Israel
Kazakh Scientific-research institute of eye diseases
Almaty Kazakhstan
Bucharest Emergency University Hospital Bucharest Romania National Institute of infectious diseases - Prof.
Dr. Matei Bals
Bucharest Romania
St Andrew's County Clinical Emergency Hospital Constanta
Constanta Romania
St Spiridon County Clinical Emergency Hospital Iasi
Iasi Romania
SC Retina SRL Bucharest Romania
Clinical Centre of Serbia Belgrade Serbia
Clinical Centre Kragujevac Kragujevac Serbia
Clinical Centre Nis Nis Serbia
Oftalmologická ambulancia Národný ústav Vyšné Hágy
Vyšné Hágy Slovakia
Istanbul University Istanbul Faculty of Medicine Department of Ophthalmology
Istanbul Turkey
Ankara Ulucanlar Ophtalmology Education Ankara Turkey
and Research Hospital
Hacettepe University Department of Ophtalmology
Ankara Turkey
Ankara University İbn-i Sina Hospita Department of Ophtalmology
Ankara Turkey
Dokuz Eylül University Hospital Department of Ophtalmology
Izmir Turkey
Istanbul Cerrahpasa University, Faculty of Medicine, Department of Ophthalmology
Istanbul Turkey
Gazi University, School of Medicine, Department of Ophthalmology
Ankara Turkey
Ondokuz Mayis University Medical Faculty Hospital
Samsun Turkey
SBÜ Prof. Dr. N. Reşat Belger Beyoğlu Ophtalmology Education and Research Hospital
Istanbul Turkey
Izmir Katip Çelebi University Department of Ophtalmology
Izmir Turkey
Ege University Medical Faculty Izmir Turkey
Umraniye Education and Research Hospital Istanbul Turkey Filatov V.P. Institute of Eye Diseases and
Tissue Therapy
Odesa Ukraine
Regional Clinical Hospital-Center of
Emergency Medicine and Disaster Medicine
Kharkiv Ukraine
Supplementary Table 6. Summary of site characteristics in the EyeCOPE study
Site informationa
N=48 n (%)b Type of site
Academic center/university hospital 36 (76.6)
Other hospital 1 (2.1)
Outpatient clinic 2 (4.3)
Private practice 8 (17.0)
Other 0 (0.0)
Missing 1
Average number of all patients examined at site per year
<100 patients 0 (0.0)
100 to <1000 patients 7 (14.9)
1000 to <10 000 patients 13 (27.7)
≥10 000 patients 27 (57.4)
Missing 1
Average number of all type uveitis patients examined at site per year
<50 patients 4 (8.7)
50 to 99 patients 3 (6.5)
100 to 999 patients 24 (52.2)
≥1000 patients 15 (32.6)
Missing 2
Average number of NIIPPU patients examined at site per yearc
<50 patients 11 (23.4)
50 to 99 patients 11 (23.4)
100 to 999 patients 15 (31.9)
≥1000 patients 10 (21.3)
Missing 1
OCT machined
Any 44 (91.7)
Spectralis/Heidelberg engineering 19 (39.6)
Cirrus/Carl Zeiss Meditec 11 (22.9)
3D-OCT/TOPCON 5 (10.4)
Stratus/Carl Zeiss Meditec 1 (2.1)
Other 14 (29.2)
aSites with valid data
bPercentages calculated based on non-missing values
cPatients with valid data
dMultiple entries were possible
OCT, optical coherence tomography; 3D, three dimensional
Supplementary Table 7. Number of certified/specialized ophthalmologists per study site
N Missing Mean (SD)
Median (min, max) Number of certified ophthalmologists
per site
47 1 13.4
(13.7)
10.0 (0, 78) Number of ophthalmologists
specialized in uveitis per site
47 1 2.5 (2.2) 2.0 (1, 10)
max, maximum; min, minimum; SD, standard deviation
Supplementary Table 8. Healthcare resource utilization due to uveitis (MAS population with healthcare visit in the preceding 12 months)
Visits for uveitisa n (%)
Seen by healthcare professional N=531
Yes 522 (98.3)
No 9 (1.7)
Seen in the emergency room N=531
Yes 95 (17.9)
No 436 (82.1)
Admission to hospital N=531
Yes 117 (22.0)
No 414 (78.0)
aParticipants who had any visits for uveitis in the preceding 12 months MAS, main analysis set
Supplementary Table 9. Summary of healthcare visits due to uveitis (MAS patients with respective visit)
N Missin
g
Mean (SD)
Median (min, max) Number of visits to healthcare
professional per month
522 0 0.5 (0.4) 0.4 (0.1, 3.3)
Number of visits to emergency room per month
94 1 0.1 (0.2) 0.1 (0.1, 1.7)
Number of days in hospital per month
93 24 1.0 (0.8) 0.8 (0.1, 4.3) MAS, main analysis set; max, maximum; min, minimum; SD, standard deviation
Supplementary Table 10. Patient-reported quality of life and work productivity (MAS population)
N Missing Mean (SD)
Median (min, max) EQ-5D-5L
Utility index 553 12 0.8 (0.2) 0.9 (-0.1, 1.0)
Self-rated (global) health status 564 1 71.7 (19.0)
75.0 (0, 100) VFQ-25
General health 562 3 48.4
(24.5)
50.0 (0.0, 100.0)
General vision 563 2 66.7
(19.4)
60.0 (0.0, 100.0)
Ocular pain 565 0 72.1
(22.7)
75.0 (0.0, 100.0)
Near activities 565 0 73.5
(26.7)
83.3 (0.0, 100.0)
Distance activities 565 0 73.6
(26.3)
83.3 (0.0, 100.0)
Social functioning 565 0 82.7
(26.2)
100.0 (0.0, 100.0)
Mental health 565 0 63.8
(27.5)
68.8 (0.0, 100.0)
Role difficulties 563 2 64.0
(31.2)
75.0 (0.0, 100.0)
Dependency 563 2 77.9
(29.9)
91.7 (0.0, 100.0)
Driving 316 249 63.2
(36.0)
75.0 (0.0, 100.0)
Color vision 562 3 89.5
(22.3)
100.0 (0.0, 100.0)
Peripheral vision 564 1 75.7
(27.2)
75.0 (0.0, 100.0)
Overall composite score 565 0 73.3
(21.8)
80.1 (8.1, 100.0) WPAI-UV
Presenteeisma 293 15 24.7
(29.1)
10.0 (0.0, 100.0)
Absenteeisma 287 21 14.6
(29.6)
0.0 (0.0, 100.0) Total work productivity
impairmenta
277 31 31.0
(32.4)
20.0 (0.0, 100.0)
Total activity impairment 557 8 32.0
(31.5)
20.0 (0.0, 100.0)
aFor presenteeism, absenteeism and total work productivity impairment only employed MAS patients were considered
EQ-5D-5L, EuroQol five dimensions five levels questionnaire; MAS, main analysis set; max,
maximum; min, minimum; SD, standard deviation; VFQ-25, Visual Function Questionnaire; WPAI-UV, Work Productivity and Activity Impairment – Uveitis
Supplementary Table 11. Ethics Committees
Country International Ethics Committee/International Review Board Argentina Independent Committee on Ethics for Clinical Pharmacology Trials
Independent Ethics committee for Clinical Training Trials Foundation of Pharmacological and Drug Studies
Brazil National Commission on Ethics in Research Ophthalmological Hospital of Sorocaba/SP
Federal University of Espirito Santo, University Hospital Cassiano Antônio de Moraes DA
Federal Univeristy of Minas Gerais
Universidade Federal de São Paulo, Hospital São Paulo – Hospital Universitario DA
Chile Ethical-Scientific Committee, Eastern Metropolitan Health Service Colombia Research Ethics Committee, Ophthalmological Foundation of
Santander
Committee of Ethics and Clinical Research, Clinica Oftalmologica del Caribe
Ethics Committee in Biomedical Research Valle del Lili Foundation
Croatia Central Ethics Committee
Republic of Croatia Agency for Medicinal products and Medical Devices
Ethical Committee, Clinical Hospital Center Osijek Ethics Committee, Clinical Hospital Center Rijeka Drug Comission, Clinical Hospital Center Zagreb
Czech Republic Ethics Committee of the General University Hospital, Prague Israel Institutional Review Board/Helsinki Committee, Galilee Medical
Center
Institutional Review Board/Helsinki Committee, Rabin Medical Center
Institutional Review Board/Helsinki Committee, Hadassah University Medical Center
Kazakhstan The Central Ethics Committee of the Ministry of Health of the Republic of Kazakhstan
Romania National Committee for Bioethics of Medicine and Medical Devices, Academy of Medical Sciences of Romania
Serbia Ethics Committee, Clinical Centre of Niš Ethics Committee, Clinical Center Kragujevac Ethics Committee, Klinical Center Vojvodine Clinical Center of Serbia, Clinic for Eye Diseases
Slovakia Ethics Committee of the National Institute of Tuberculosis, Lung Diseases, and Thoracic Surgery, Vysne Hagy
Switzerland Cantonal Ethics Committee for Research, Health and Welfare Directorate of the Canton of Bern
Turkey Research Ethics Committee, Istanbul University, Fatih/Istanbul Ukraine Ethics Committee of Regional Clinial Hospital Center of Medical Aid
and Catastrophe Medicine, 13 Nezalezhnosti Ave Kharkiv 61058 Committee on Bioethics at Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of
Ukraine
Reference
1. Colenbrander A. Introduction to Visual Acuity Measurement. Available at:
https://www.precision-vision.com/wp-content/uploads/2020/01/VA-Man01312020.pdf.
Accessed June 17, 2020.
